The novel Coronavirus SARS-CoV-2 is the viral pathogen responsible for the ongoing global pandemic, COVID-19 (Coronavirus disease 2019). To date, the data recorded indicate 1.62 Mln deaths and 72.8 Mln people infected (WHO situation report Dec 2020). On December 27, the first anti-COVID-19 vaccinations started in Europe. There are no direct antivirals against SARS-CoV-2. Understanding the pathophysiological and inflammatory/immunological processes of SARS-CoV-2 infection is essential to identify new drug therapies. In the most severe COVID-19 cases, an unregulated immunological/inflammatory system results in organ injury that can be fatal to the host in some cases. Pharmacologic approaches to normalize the unregulated inflammatory/immunologic response is an important therapeutic solution. Evidence associates a non-regulation of the “complement system” as one of the causes of generalized inflammation causing multi-organ dysfunction. Serum levels of a complement cascade mediator, factor “C5a”, have been found in high concentrations in the blood of COVID-19 patients with severe disease. In this article we discuss the correlation between complement system and COVID-19 infection and pharmacological solutions directed to regulate.

新型冠状病毒SARS-CoV-2是导致持续不断的全球大流行COVID-19的病毒病原体（Coronavirus disease 2019）。迄今为止，记录的数据表明有162万人死亡和7280万人被​​感染（世卫组织情况报告，2020年12月）。12月27日，欧洲开始了首次抗COVID-19的疫苗接种。没有针对SARS-CoV-2的直接抗病毒药。了解SARS-CoV-2感染的病理生理学和炎性/免疫学过程对于确定新药疗法至关重要。在最严重的COVID-19病例中，免疫/炎症系统失调会导致器官损伤，在某些情况下可能对宿主造成致命伤害。使未调节的炎症/免疫反应正常化的药理学方法是重要的治疗方案。证据表明，“补体系统”的失调是引起多器官功能障碍的全身性炎症的原因之一。已在患有严重疾病的COVID-19患者的血液中发现了高浓度的补体级联介质“ C5a”的血清水平。在本文中，我们讨论补体系统与COVID-19感染之间的相关性以及针对调节的药理解决方案。